Hormone Therapy Alternatives Snapshot

Hormone Therapy Alternatives Snapshot can be a place to start if you are searching for information about hormone therapy alternatives.

2023 Nonhormone Therapy Position Statement of The North American Menopause Society

What were the Results in the 2023 Nonhormone Therapy Position Statement of The North American Menopause Society?

On page one in the The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society: Abstract – Results, published May 2023, the results were:

“Results: Evidence-based review of the literature resulted in several nonhormone options for the treatment of vasomotor symptoms.

Recommended: Cognitive-behavioral therapy, clinical hypnosis, selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors, gabapentin, fezolinetant (Level I); oxybutynin (Levels I-II); weight loss, stellate ganglion block (Levels II-III).

Not recommended: Paced respiration (Level I); supplements/herbal remedies (Levels I-II); cooling techniques, avoiding triggers, exercise, yoga, mindfulness-based intervention, relaxation, suvorexant, soy foods and soy extracts, soy metabolite equol, cannabinoids, acupuncture, calibration of neural oscillations (Level II); chiropractic interventions, clonidine; (Levels I-III); dietary modification and pregabalin (Level III)”.

What do the Levels mean in the 2023 Nonhormone Therapy Position Statement of The North American Menopause Society?

On page one in the The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society: Abstract – Methods the North American Menopause Society (NAMS) elaborate on:

“Methods: The panel assessed the most current and available literature to determine whether to recommend or not recommend use based on these levels of evidence:

Level I, good and consistent scientific evidence
Level II, limited or inconsistent scientific evidence
Level III, consensus and expert opinion”.³

Where may I find Links related to the 2023 Nonhormone Therapy Position Statement of The North American Menopause Society?

Your Country may have Links similar to:

Fezolinetant (Veozah)

What is Fezolinetant (Veozah)?

In FDA Approves Novel Drug To Treat Moderate To Severe Hot Flashes Caused By Menopause, published 12 May 2023, the (United States) Food and Drug Administration (FDA) elaborate on:

“Today, the U.S. Food and Drug Administration approved Veozah (fezolinetant), an oral medication for the treatment of moderate to severe vasomotor symptoms, or hot flashes, caused by menopause. Veozah is the first neurokinin 3 (NK3) receptor antagonist approved by the FDA to treat moderate to severe hot flashes from menopause. It works by binding to and blocking the activities of the NK3 receptor, which plays a role in the brain’s regulation of body temperature”.

Where may I find Links to a video about the FDA’s approval of Veozah?

Your Country may have Links similar to:

Video Series-2023: New FDA-Approved Nonhormone Option for the Treatment of Hot Flashes

Health Topics A-Z

Where may I find Health Topics A-Z related to Hormone Therapy Alternatives Snapshot?

In Health Topics A-Z you may find:

Health Topics A-Z

Links

Where may I find Links related to Hormone Therapy Alternatives Snapshot?

Your Country may have Links similar to:

Links

This Links List to third party websites is neither comprehensive nor exhaustive. Inclusion on this Links List does not imply endorsement or recommendation. Non-inclusion on this Links List does not imply non-endorsement or non-recommendation. Third party websites are not under the control of Meno Martha International Menopause Directory. Third party websites may contain explicit medical images and/or sexual references. Please read Meno Martha International Menopause Directory’s Links Policy before proceeding to a Link. Please contact Webmaster if you experience a problem with a Link.